Find Clinical Trial

The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study.


← Back
Study Phase

Phase 3

Therapeutic Area

Rheumatology

IndicationOsteoarthritis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

STRONTIUM RANELATE,
S012911

Active Substance CodeS012911
Protocol CodeCL3-12911-018
EudraCT Code2005-002494-75
ISRCTN CodeISRCTN41323372


Documents and links

Results summary READ MORE
First scientific publication READ MORE
Second scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility